Table 1.
Patient characteristics of University of California—San Francisco (UCSF) and University Hospital Zurich (USZ) datasets.
| Patient/tumor characteristic | Total UCSF data | USZ data | P | |
|---|---|---|---|---|
| N = 1,404 | N = 237 | |||
| Sex (%) | Male | 571 (41) | 128 (54) | <0.01 |
| Female | 833 (59) | 109 (46) | ||
| Median age ± SD | 59 (13) | 62 (12) | 0.03 | |
| KPS (%) | 80–100 | 1,053 (75) | 198 (83) | <0.01 |
| 40–80 | 351 (25) | 37 (16) | <0.01 | |
| 10–40 | 0 (0) | 2 (1) | – | |
| Primary tumor location (%) | Lung | 530 (38) | 136 (58) | <0.01 |
| Breast | 357 (25) | 27 (11) | <0.01 | |
| Melanoma | 272 (19) | 74 (31) | <0.01 | |
| Kidney | 91 (7) | 0 (0) | – | |
| Gastrointestinal | 57 (4) | 0 (0) | – | |
| Gynecologic | 27 (2) | 0 (0) | – | |
| Sarcoma | 20 (1) | 0 (0) | – | |
| Other | 50 (4) | 0 (0) | – | |
| Histology primary tumor (%) | Adenocarcinoma | 802 (57) | 124 (52) | 0.17 |
| Melanoma | 272 (19) | 74 (31) | <0.01 | |
| Renal cell carcinoma | 88 (6) | 0 (0) | – | |
| Small cell carcinoma | 44 (3) | 0 (0) | – | |
| Squamous cell carcinoma | 40 (3) | 10 (4) | 0.26 | |
| Sarcoma | 18 (1) | 0 (0) | – | |
| Large cell carcinoma | 9 (0.6) | 2 (1) | 0.72 | |
| Bone carcinoma | 8 (0.6) | 0 (0) | – | |
| Adeno squamous carcinoma | 6 (0.4) | 0 (0) | – | |
| Broncho alveolar cell carcinoma | 5 (0.4) | 0 (0) | – | |
| Germ cell carcinoma | 2 (0.1) | 0 (0) | – | |
| Lymphoma | 1 (0.1) | 0 (0) | – | |
| Other/NOS | 109 (8) | 27 (11) | 0.06 | |
| Primary controlled | 974 (70) | 149 (63) | 0.05 | |
| ECM present | 1,097 (78) | 190 (80) | 0.48 | |
| Number of lesions per patient at treatment | Median ± SD | 3 (7) | 2 (3) | <0.01 |
| Symptoms | Headaches | 437 (31) | 31 (13) | <0.01 |
| Hypertension | 407 (29) | 0 (0) | < 0.01 | |
| Seizures | 134 (10) | 16 (7) | 0.17 | |
| Diabetes | 98 (7) | 13 (6) | 0.4 | |
| CTD | 21 (2) | 2 (1) | 0.43 | |
| Number of lesions in total | 7,974 | 646 | – | |
| Number of ARE cases (% of total lesions) | 217 (2.7) | 20 (3.1) | 0.61 | |
| Number of patients with ARE (% of total patients) | 155 (11) | 19 (8) | 0.16 | |
| Prescription dose ± SD (Gy) | 18.5 (1.5) | 20 (5.0) | – | |
The P-value of two-proportion z-test or unpaired two-sample t-test for significant differences between datasets was reported for each characteristic if applicable.
SD, standard deviation; KPS, Karnofsky performance score (80–100, good performance; 50–70, medium performance; and 10–40 bad performance); ECM, extracranial metastasis; BM, brain metastasis; CTD, connective tissue disorder; ARE, adverse radiation effect; Gy, gray.